Frederick L. Ruberg | oneAMYLOIDOSISvoice

Frederick L. Ruberg, MD

Associate Chief, Academic Affairs, Section of Cardiovascular Medicine
Associate Director, Cardiovascular Medicine Fellowship Training Program
Director, Pilot Grants Program, Boston University Clinical and Translational Science Institute
Director, Advanced Cardiac Imaging Program
Section of Cardiovascular Medicine, Department of Medicine
Department of Radiology
Boston Medical Center
Boston, Massachusetts, United States

Frederick L. Ruberg, MD is an Associate Professor of Medicine and Radiology at Boston University (BU) School of Medicine and clinical cardiologist at Boston Medical Center (BMC), specializing in cardiac imaging and infiltrative heart disease. He attended the University of Pennsylvania School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, and a fellowship in cardiovascular magnetic resonance imaging at Beth Israel Deaconess Medical Center.

Dr. Ruberg has an active clinical practice as the senior cardiologist in the BU/BMC Amyloidosis Center. He is Associate Chief of Cardiovascular Medicine for Academic Affairs, Associate Director of the Cardiovascular Medicine Fellowship program, director of the cardiac MRI program at BMC as well as the Integrated Pilot Grants Program of the Boston University Clinical and Translational Science Institute.

Dr. Ruberg is also an Associate Editor of Circulation: Cardiovascular Imaging and a Fellow of the American Heart Association and American College of Cardiology. His NIH and industry funded research program focuses on the application of non-invasive cardiac imaging for amyloidosis identification and clinical care optimization. Dr. Ruberg’s active area of research interest is ATTR amyloidosis. Current projects involve the application of pyrophosphate imaging for detection of ATTR amyloidosis, application of echocardiographic strain imaging as a disease marker, evaluation of treatments of ATTR amyloidosis, and validation of point of care diagnostic tools for cardiac amyloidosis identification in the outpatient clinic. Dr. Ruberg is committed to raising awareness of cardiac amyloidosis among clinicians and the general population so as to afford early diagnosis and enhanced access to disease modifying therapies.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.